Structural Optimization of HPMA Copolymer-based Dexamethasone Prodrug for Improved Treatment of Inflammatory Arthritis

Overview

Journal J Control Release

Specialty Pharmacology

Date 2020 May 24

PMID 32445658

Citations 14

Authors

Zhenshan Jia

Gang Zhao

Xin Wei

Dexuan Kong

Yuanyuan Sun

You Zhou

Subodh M Lele

Edward V Fehringer

Kevin L Garvin

Steven R Goldring

Dong Wang

Affiliations

Soon will be listed here.

Abstract

Despite their notorious adverse effects, glucocorticoids (GC, potent anti-inflammatory drugs) are used extensively in clinical management of rheumatoid arthritis (RA) and other chronic inflammatory diseases. To achieve a sustained therapeutic efficacy and reduced toxicities, macromolecular GC prodrugs have been developed with promising outcomes for the treatment of RA. Fine-tuning the activation kinetics of these prodrugs may further improve their therapeutic efficacy and minimize the off-target adverse effects. To assess the feasibility of this strategy, five different dexamethasone (Dex, a potent GC)-containing monomers with distinctively different linker chemistries were designed, synthesized, and copolymerized with N-(2-hydroxypropyl) methacrylamide (HPMA) to obtain 5 macromolecular Dex prodrugs. Their Dex releasing rates were analyzed in vitro and shown to display a wide spectrum of activation kinetics. Their therapeutic efficacy and preliminary toxicology profiles were assessed and compared in vivo in an adjuvant-induced arthritis (AA) rat model in order to identify the ideal prodrug design for the most effective and safe treatment of inflammatory arthritis. The in vivo data demonstrated that the C3 hydrazone linker-containing prodrug design was the most effective in preserving joint structural integrity. The results from this study suggest that the design and screening of different activation mechanisms may help to identify macromolecular prodrugs with the most potent therapeutic efficacy and safety for the management of inflammatory arthritis.

Citing Articles

Identification of formulation parameters that affect the analgesic efficacy of ProGel-Dex - A thermoresponsive polymeric dexamethasone prodrug for chronic arthritis pain relief.

Wei X, Zhao G, Chen N, Xu X, Jiang H, Tran D Nanomedicine. 2024; 62:102782.

PMID: 39179013 PMC: 11687284. DOI: 10.1016/j.nano.2024.102782.

Glucocorticoids-based prodrug design: Current strategies and research progress.

Liu H, Ji M, Xiao P, Gou J, Yin T, He H Asian J Pharm Sci. 2024; 19(3):100922.

PMID: 38966286 PMC: 11222810. DOI: 10.1016/j.ajps.2024.100922.

Stimuli-sensitive polymer prodrug nanocarriers by reversible-deactivation radical polymerization.

Guerassimoff L, Ferrere M, Bossion A, Nicolas J Chem Soc Rev. 2024; 53(12):6511-6567.

PMID: 38775004 PMC: 11181997. DOI: 10.1039/d2cs01060g.

Context is key: glucocorticoid receptor and corticosteroid therapeutics in outcomes after traumatic brain injury.

Taylor M, Kokiko-Cochran O Front Cell Neurosci. 2024; 18:1351685.

PMID: 38529007 PMC: 10961349. DOI: 10.3389/fncel.2024.1351685.

Thermoresponsive Polymeric Hydromorphone Prodrug Provides Sustained Local Analgesia without Apparent Adverse Effects.

Jia Z, Wei X, Chen N, Xu X, Zhao G, Fu X Mol Pharm. 2024; 21(4):1838-1847.

PMID: 38413029 PMC: 11210938. DOI: 10.1021/acs.molpharmaceut.3c01133.

References

Quan L, Zhang Y, Crielaard B, Dusad A, Lele S, Rijcken C . Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes. ACS Nano. 2013; 8(1):458-466. PMC: 3947749. DOI: 10.1021/nn4048205. View

De Cock D, Van der Elst K, Meyfroidt S, Verschueren P, Westhovens R . The optimal combination therapy for the treatment of early rheumatoid arthritis. Expert Opin Pharmacother. 2015; 16(11):1615-25. DOI: 10.1517/14656566.2015.1056735. View

Ren K, Yuan H, Zhang Y, Wei X, Wang D . Macromolecular glucocorticoid prodrug improves the treatment of dextran sulfate sodium-induced mice ulcerative colitis. Clin Immunol. 2015; 160(1):71-81. DOI: 10.1016/j.clim.2015.03.027. View

Yuan F, Tabor D, Nelson R, Yuan H, Zhang Y, Nuxoll J . A dexamethasone prodrug reduces the renal macrophage response and provides enhanced resolution of established murine lupus nephritis. PLoS One. 2013; 8(11):e81483. PMC: 3842961. DOI: 10.1371/journal.pone.0081483. View

Longo U, Petrillo S, Denaro V . Current Concepts in the Management of Rheumatoid Hand. Int J Rheumatol. 2015; 2015:648073. PMC: 4510119. DOI: 10.1155/2015/648073. View

Fonseca Ferreira J, Ahmed Mohamed A, Emery P . Glucocorticoids and Rheumatoid Arthritis. Rheum Dis Clin North Am. 2015; 42(1):33-46, vii. DOI: 10.1016/j.rdc.2015.08.006. View

Smolen J, Aletaha D, Barton A, Burmester G, Emery P, Firestein G . Rheumatoid arthritis. Nat Rev Dis Primers. 2018; 4:18001. DOI: 10.1038/nrdp.2018.1. View

Quan L, Purdue P, Liu X, Boska M, Lele S, Thiele G . Development of a macromolecular prodrug for the treatment of inflammatory arthritis: mechanisms involved in arthrotropism and sustained therapeutic efficacy. Arthritis Res Ther. 2010; 12(5):R170. PMC: 2990997. DOI: 10.1186/ar3130. View

Stolina M, Bolon B, Middleton S, Dwyer D, Brown H, Duryea D . The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis. J Clin Immunol. 2008; 29(2):158-74. DOI: 10.1007/s10875-008-9238-8. View

10.

Quan L, Zhang Y, Dusad A, Ren K, Purdue P, Goldring S . The Evaluation of the Therapeutic Efficacy and Side Effects of a Macromolecular Dexamethasone Prodrug in the Collagen-Induced Arthritis Mouse Model. Pharm Res. 2015; 33(1):186-93. PMC: 4690754. DOI: 10.1007/s11095-015-1776-1. View

11.

Danelich I, Wright S, Lose J, Tefft B, Cicci J, Reed B . Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease. Pharmacotherapy. 2015; 35(5):520-35. DOI: 10.1002/phar.1584. View

12.

Gabriel S . The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 2001; 27(2):269-81. DOI: 10.1016/s0889-857x(05)70201-5. View

13.

Timofeevski S, Panarin E, Vinogradov O, Nezhentsev M . Anti-inflammatory and antishock water-soluble polyesters of glucocorticoids with low level systemic toxicity. Pharm Res. 1996; 13(3):476-80. DOI: 10.1023/a:1016069315423. View

14.

Yuan F, Quan L, Cui L, Goldring S, Wang D . Development of macromolecular prodrug for rheumatoid arthritis. Adv Drug Deliv Rev. 2012; 64(12):1205-19. PMC: 3572768. DOI: 10.1016/j.addr.2012.03.006. View

15.

Quan L, Thiele G, Tian J, Wang D . The Development of Novel Therapies for Rheumatoid Arthritis. Expert Opin Ther Pat. 2009; 18(7):723-738. PMC: 2491719. DOI: 10.1517/13543776.18.7.723. View

16.

Yu M, Wu X, Lin B, Han J, Yang L, Han S . Lysosomal pH Decrease in Inflammatory Cells Used To Enable Activatable Imaging of Inflammation with a Sialic Acid Conjugated Profluorophore. Anal Chem. 2015; 87(13):6688-95. DOI: 10.1021/acs.analchem.5b00847. View

17.

Wang D, Miller S, Liu X, Anderson B, Wang X, Goldring S . Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. Arthritis Res Ther. 2007; 9(1):R2. PMC: 1860059. DOI: 10.1186/ar2106. View

18.

Bao L, Zhu Y, Elhassan A, Wu Q, Xiao B, Zhu J . Adjuvant-induced arthritis: IL-1 beta, IL-6 and TNF-alpha are up-regulated in the spinal cord. Neuroreport. 2001; 12(18):3905-8. DOI: 10.1097/00001756-200112210-00010. View

19.

Rasch L, Bultink I, van Tuyl L, Lems W . Glucocorticoid safety for treating rheumatoid arthritis. Expert Opin Drug Saf. 2015; 14(6):839-44. DOI: 10.1517/14740338.2015.1027681. View

20.

Liu X, Quan L, Tian J, Alnouti Y, Fu K, Thiele G . Synthesis and evaluation of a well-defined HPMA copolymer-dexamethasone conjugate for effective treatment of rheumatoid arthritis. Pharm Res. 2008; 25(12):2910-9. PMC: 2593120. DOI: 10.1007/s11095-008-9683-3. View